Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV®) and measles or measles-mumps-rubella vaccines in 8–9 months-old Indian children

We evaluated safety, reactogenicity, and immunogenicity when the WHO-prequalified single-dose Typhoid Vi-polysaccharide conjugate vaccine, Typbar-TCV®, was administered concomitantly with measles (MV) or measles-mumps-rubella (MMR) vaccines in 8- or 9-month-old children. We enrolled 493 children who...

Descripción completa

Detalles Bibliográficos
Autores principales: Vadrevu, Krishna Mohan, Dugyala, Raju, Mahantashetti, Niranjana Shamulinga, Khalatkar, Vasant, Murthy, Krishna, Mogre, Sandeep, Mitra, Monjori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Licensed Vaccines – Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762751/
https://www.ncbi.nlm.nih.gov/pubmed/36476258
http://dx.doi.org/10.1080/21645515.2022.2150030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762751/
https://www.ncbi.nlm.nih.gov/pubmed/36476258
http://dx.doi.org/10.1080/21645515.2022.2150030

Ejemplares similares